What is HC Wainwright’s Estimate for KROS FY2026 Earnings?

Keros Therapeutics, Inc. (NASDAQ:KROS) – Investment analysts at HC Wainwright upped their FY2026 EPS estimates for Keros Therapeutics in a research note issued on Friday, November 6th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($3.33) for the year, up from their prior forecast of ($4.62). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.27) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q4 2026 earnings at ($1.39) EPS, Q1 2027 earnings at ($1.45) EPS, Q2 2027 earnings at ($1.52) EPS, Q3 2027 earnings at ($0.62) EPS, Q4 2027 earnings at ($1.65) EPS, FY2027 earnings at ($5.25) EPS, FY2028 earnings at ($5.86) EPS, FY2029 earnings at ($3.55) EPS and FY2030 earnings at ($1.15) EPS.

Several other research analysts have also weighed in on the company. Wells Fargo & Company lowered their price objective on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Leerink Partners cut their target price on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. Zacks Research raised Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Finally, Wall Street Zen upgraded Keros Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Keros Therapeutics presently has an average rating of “Hold” and a consensus price target of $21.40.

Keros Therapeutics Trading Down 2.0%

Shares of Keros Therapeutics stock opened at $9.17 on Tuesday. The business has a 50-day moving average price of $11.14 and a two-hundred day moving average price of $11.87. Keros Therapeutics has a 1-year low of $9.10 and a 1-year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Thursday, November 5th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $1.66. The business had revenue of $40.01 million for the quarter, compared to analyst estimates of $14.76 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in KROS. Diversified Trust Co acquired a new stake in shares of Keros Therapeutics in the 3rd quarter worth about $133,000. Squarepoint Ops LLC bought a new position in Keros Therapeutics in the 2nd quarter valued at about $334,000. Hsbc Holdings PLC boosted its stake in Keros Therapeutics by 29.5% during the 2nd quarter. Hsbc Holdings PLC now owns 69,926 shares of the company’s stock valued at $761,000 after purchasing an additional 15,940 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in Keros Therapeutics during the 2nd quarter valued at about $15,091,483. Finally, Empowered Funds LLC bought a new stake in Keros Therapeutics during the 2nd quarter worth approximately $1,521,000. 71.56% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the transaction, the insider owned 27,559 shares in the company, valued at approximately $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 5,343 shares of company stock worth $54,985 in the last 90 days. Corporate insiders own 12.60% of the company’s stock.

Keros Therapeutics announced that its Board of Directors has approved a share repurchase program on Wednesday, September 9th that authorizes the company to repurchase $5 million in shares. This buyback authorization authorizes the company to repurchase up to 2.3% of its stock through open market purchases. Share buyback programs are generally an indication that the company’s management believes its stock is undervalued.

More Keros Therapeutics News

Here are the key news stories impacting Keros Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $3.33 from a loss of $4.62, and its FY2027 estimate to a loss of $5.25 from a loss of $6.39. It also modestly improved its Q4 2026 forecast. The firm maintained a Buy rating and $20 price target. Keros Therapeutics analyst information
• Neutral Sentiment: Wall Street Zen upgraded KROS to Hold, a modestly improved rating that is less bullish than a Buy recommendation. Keros Therapeutics upgraded to Hold at Wall Street Zen
• Negative Sentiment: Despite the near-term upward revisions, HC Wainwright lowered its EPS forecasts for FY2028, FY2029 and FY2030. Its estimates still imply losses in each of those years, signaling that profitability remains a long-term challenge.

About Keros Therapeutics

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.